Brain-based biomarkers of likely drug response were associated with a greater mean reduction in reported PTSD symptoms in a study of patients treated with ALTO-100.
Alto Neuroscience said in a press release that the topline results indicate that its drug ALTO-100 was safe and effective in patients with PTSD. The study also provides evidence the company’s precision medicine platform can match drugs to patients who would benefit from them, according to the release.
Positive results from another arm of the study examining ALTO-100 in major depressive disorder (MDD) were announced in January.
“This